Email Updates

Search form

You are here

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

Include in
Published Research

The highly attenuated rcAd26.MOS1.HIV-Env vaccine was well tolerated up to 10^11 VP in healthy, HIV-1-uninfected adults, though the single dose was poorly immunogenic suggesting the replicative capacity of the vector was too attenuated. There was no evidence of shedding of infectious virus or secondary vaccine transmission following the isolation period. These data suggest the use of less attenuated viral vectors in future studies of live, oral HIV-1 vaccines.

November 14, 2018
PLoS One